122086 < FHD — 360p >

: The evidence underscores the need for better integration between primary and secondary care to ensure that pharmacists can perform their safety-critical roles effectively. Summary of Recommendations The write-up of this evidence suggests a need for:

: For conditions like Parkinson's, the timing of medication is vital. Variations in how "controlled release" (CR) versions of drugs (e.g., Sinemet CR) are handled by pharmacies or communicated by GPs can lead to unsettling and time-consuming complications for the patient. Communication Gaps in Healthcare

: Mandatory consultation before changing a patient's medication brand, especially for time-critical drugs. 122086

: Acknowledging that the "inactive" ingredients in generic drugs can have active, detrimental effects on specific patient groups. Written evidence submitted by Group 3 (Event 1) (APE0044)

: Different manufacturers use varying binding agents that can trigger adverse reactions in patients. In one cited case, a change in Parkinson’s medication caused a patient to go from being stable and independent to being unable to speak or feed themselves within four days. : The evidence underscores the need for better

In the context of the UK Parliament, refers to specific written evidence submitted to the Health and Social Care Committee regarding pharmacy services and medication management .

Beyond individual patient testimony, the broader inquiry (often associated with such evidence) explores the sustainability of community pharmacies. In one cited case, a change in Parkinson’s

Evidence under reference 122086 illustrates the severe consequences when medication regimes—particularly for long-term metabolic or neurological conditions—are disrupted. A key issue identified is the between different brands of the same drug.